Related Experiment Video
Updated: Apr 8, 2026

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
Published on: May 16, 2021
The Paradoxical Effects of AMPK on Insulin Gene Expression and Glucose-Induced Insulin Secretion
Ji-Won Kim1, Young-Hye You1, Dong-Sik Ham1
1Department of Endocrinology & Metabolism, The Catholic University of Korea, Seoul, 137-040, Korea.
Abstract:
The activation of AMP-activated protein kinase (AMPK) is known to repress the expression of the insulin gene and glucose-stimulated insulin secretion (GSIS). However, the mechanisms by which this occurs, as well as the effects of AMPK activation on glucolipotoxicity-induced β-cell dysfunction, have not been elucidated. To investigate the effects of 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR) and peroxisome proliferator-activated receptorγ-coactivator-1α (PGC-1α) on β-cell-specific genes under glucolipotoxic conditions, we performed real-time PCR and measured insulin secretion by primary islets. To study these effects in vivo, we administered AICAR for 10 days (1 mg/g body weight) to 90% pancreatectomized hyperglycemic mice. The exposure of isolated rat and human islets to glucolipotoxic conditions and the overexpression of PGC-1α suppressed insulin and NEUROD1 mRNA expression. However, the expression of these genes was preserved by AICAR treatment and by PGC-1α inhibition. Exposure of isolated islets to glucolipotoxic conditions for 3 days decreased GSIS, which was also well maintained by AICAR treatment and by PGC-1α inhibition. The administration of AICAR to 90% pancreatectomized hyperglycemic mice improved glucose tolerance and insulin secretion. These results indicate that treatment of islets with an AMPK agonist under glucolipotoxic conditions protects against glucolipotoxicity-induced β-cell dysfunction. A better understanding of the functions of molecules such as PGC-1α and AMPK, which play key roles in intracellular fuel regulation, could herald a new era for the treatment of patients with type 2 diabetes mellitus by providing protection against glucolipotoxicity.
Insights
AMP-activated protein kinase (AMPK) activation protects against glucolipotoxicity-induced pancreatic beta-cell dysfunction. This study shows that AMPK activation preserves insulin gene expression and glucose-stimulated insulin secretion (GSIS) under harmful conditions.
Area of Science:
- Metabolic regulation
- Cellular dysfunction
- Diabetes research
Background:
- AMP-activated protein kinase (AMPK) activation is known to inhibit insulin gene expression and glucose-stimulated insulin secretion (GSIS).
- Mechanisms underlying AMPK's effects on beta-cell function and its role in glucolipotoxicity remain unclear.
- Glucolipotoxicity contributes to beta-cell dysfunction, a hallmark of type 2 diabetes mellitus.
Purpose of the Study:
- To investigate the impact of 5-amino-4-imidazolecarboxamide ribonucleotide (AICAR), an AMPK activator, and peroxisome proliferator-activated receptor-gamma coactivator-1 alpha (PGC-1α) on beta-cell-specific genes under glucolipotoxic conditions.
- To evaluate the protective effects of AICAR against glucolipotoxicity-induced beta-cell dysfunction in vitro and in vivo.
- To explore the role of PGC-1α in mediating these effects.
Main Methods:
- Real-time PCR was used to measure mRNA expression of insulin and NEUROD1 in isolated rat and human islets.
- Insulin secretion was assessed in response to glucose stimulation.
- AICAR was administered to hyperglycemic mice with 90% pancreatectomy to assess in vivo effects on glucose tolerance and insulin secretion.
Main Results:
- Glucolipotoxicity and PGC-1α overexpression suppressed insulin and NEUROD1 mRNA expression in isolated islets.
- AICAR treatment and PGC-1α inhibition preserved insulin and NEUROD1 mRNA expression under glucolipotoxic conditions.
- AICAR treatment and PGC-1α inhibition maintained GSIS in islets exposed to glucolipotoxicity.
- In vivo, AICAR administration improved glucose tolerance and insulin secretion in hyperglycemic mice.
Conclusions:
- AMPK activation, via AICAR treatment, protects pancreatic beta-cells against glucolipotoxicity-induced dysfunction.
- AMPK activation preserves key beta-cell genes and insulin secretion under detrimental metabolic conditions.
- Targeting AMPK and PGC-1α may offer novel therapeutic strategies for type 2 diabetes by mitigating glucolipotoxicity.
Related Concept Videos
cAMP-dependent Protein Kinase Pathways
Insulin: The Receptor and Signaling Pathways
Cell Specific Gene Expression
PI3K/mTOR/AKT Signaling Pathway
Hormones Regulating Blood Glucose
In addition to accelerating glucose uptake and utilization, insulin has...
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
Insulin and C-peptide are...

